Study guide
13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline
Key Takeaways Explain This Topic AI
The 2026 ACC/AHA dyslipidemia guideline replaces the Pooled Cohort Equations with the PREVENT-ASCVD calculator for adults aged 30–79, with 10-year risk tiers of low (<3%), borderline (3% to <5%), intermediate (5% to <10%), and high (≥10%).
LDL-C goals are back: <100 mg/dL for borderline or intermediate primary-prevention risk, <70 mg/dL for high primary-prevention risk, and <55 mg/dL (non-HDL-C <85 mg/dL) for very-high-risk secondary prevention.
Lipoprotein(a) should be measured at least once; a level ≥125 nmol/L (50 mg/dL) is a risk-enhancing factor that supports more intensive LDL-C lowering.
Female-specific enhancers such as preeclampsia and other adverse pregnancy outcomes, menopause before 40, PCOS, and autoimmune disease help personalize the PREVENT estimate toward treatment.
Statins are generally stopped before conception and avoided in pregnancy and breastfeeding, although the FDA removed the absolute pregnancy contraindication in 2021 for very-high-risk patients.
Last updated: October 2026
Why Lipids Matter for Women
Atherosclerotic cardiovascular disease (ASCVD)—coronary heart disease, ischemic stroke, and peripheral artery disease—is the leading cause of death in U.S. women. LDL cholesterol rises and HDL function declines across the menopausal transition, so risk climbs steeply after menopause. Women are still less likely than men to be offered statins or to reach lipid goals, which is why WHNPs must apply the guideline actively rather than waiting for symptoms.
On March 13, 2026 , the ACC, AHA, and nine partner societies published a new dyslipidemia guideline that replaced the 2018 cholesterol guideline. Its themes are: treat earlier in life, estimate risk with PREVENT instead of the Pooled Cohort Equations, and bring back numeric LDL-C and non-HDL-C goals .
Screening & the Standard Lipid Panel
Who and when: A fasting or non-fasting lipid profile in adults starting at age 20 (the guideline also endorses universal childhood screening at ages 9–11), repeated about every 4–6 years when risk is low and more often when risk factors change.
Non-fasting is acceptable for most patients. If triglycerides are ≥400 mg/dL, repeat fasting or use a calculation (Martin-Hopkins or Sampson) that stays accurate at high triglycerides, or measure LDL-C directly.
Lipoprotein(a): Measure at least once in adulthood; it is largely genetic and stable.
Apolipoprotein B: Optional; most useful when triglycerides exceed 200 mg/dL, in diabetes, or when LDL-C is already <70 mg/dL but residual risk is suspected.
- Parameter Target or Threshold Clinical Note
- LDL-C Goal set by risk: <100, <70, or <55 mg/dL Primary treatment target; percentage reduction also matters
Non-HDL-C About 30 mg/dL above the LDL-C goal (for example, <85 mg/dL when the LDL-C goal is <55) Captures triglyceride-rich remnant particles
HDL-C Low if <50 mg/dL in women A risk marker; drugs that raise HDL do not reduce events
Triglycerides Normal <150 mg/dL ≥500 mg/dL raises pancreatitis risk; ≥1,000 mg/dL is a strong indication for triglyceride-lowering therapy
Lipoprotein(a) Enhancer at ≥125 nmol/L (50 mg/dL) About 1.4-fold higher risk; ≥250 nmol/L (100 mg/dL) is about 2-fold
The "CPR" Approach with PREVENT-ASCVD
The 2026 guideline frames primary-prevention decisions for adults aged 30–79 with LDL-C 70–189 mg/dL and no ASCVD as C-P-R :
Calculate 10-year (and 30-year) risk with the PREVENT-ASCVD equations, which add kidney function (eGFR), account for current statin and antihypertensive use, and remove race.
Personalize that estimate with factors PREVENT does not capture, such as lipoprotein(a), family history of premature ASCVD, and female-specific enhancers.
Reclassify and reassess , selectively using coronary artery calcium (CAC) scoring in women aged 45 or older (men 40 or older) when the decision is uncertain.
10-Year PREVENT-ASCVD Risk Category Lipid-Lowering Approach LDL-C Goal
<3% Low Lifestyle; consider drug therapy if LDL-C ≥160 mg/dL or there is a strong family history of premature ASCVD —
3% to <5% Borderline LDL-lowering therapy can be considered , especially with risk enhancers <100 mg/dL
5% to <10% Intermediate LDL-lowering therapy should be considered after a clinician–patient discussion <100 mg/dL
≥10% High LDL-lowering therapy recommended <70 mg/dL
Other groups do not need a calculator: adults aged 40–75 with diabetes, CKD stage 3–4, or HIV are recommended LDL-lowering therapy regardless of LDL-C; an LDL-C ≥190 mg/dL suggests familial hypercholesterolemia and calls for high-intensity statin therapy; and in secondary prevention , most patients with clinical ASCVD qualify for an LDL-C goal of <55 mg/dL (very high risk), with a goal of at least <70 mg/dL for the rest.
Coronary Artery Calcium
A CAC score of 0 in a borderline- or intermediate-risk woman reclassifies her risk downward and supports deferring drug therapy, unless she smokes, has diabetes, or has a strong family history. Any CAC above zero, and especially a score of 100 or more (or ≥75th percentile for age and sex), favors treatment and a lower LDL-C goal.
Female-Specific & Female-Predominant Risk Enhancers
Enhancer Why It Matters
Adverse pregnancy outcomes Preeclampsia, gestational hypertension, gestational diabetes, preterm birth, and small-for-gestational-age birth reveal early vascular and metabolic vulnerability; preeclampsia roughly doubles later coronary disease and stroke risk.
Premature menopause (<40 years) Spontaneous POI or surgical oophorectomy before 40 brings early estrogen loss, arterial stiffening, and adverse lipid shifts.
PCOS Insulin resistance and visceral adiposity produce high triglycerides, low HDL-C, and small dense LDL.
Autoimmune disease Lupus and rheumatoid arthritis accelerate atherosclerosis; young women with lupus have many-fold higher myocardial infarction risk.
Other markers Persistent triglycerides ≥175 mg/dL, hs-CRP ≥2 mg/L, lipoprotein(a) ≥125 nmol/L, elevated apoB, ankle-brachial index <0.9.
Lipid-Lowering Pharmacotherapy
Statins (first-line): High intensity lowers LDL-C ≥50% (atorvastatin 40–80 mg, rosuvastatin 20–40 mg); moderate intensity lowers it 30%–49% (atorvastatin 10–20 mg, rosuvastatin 5–10 mg, simvastatin 20–40 mg, pravastatin 40–80 mg). Myalgias are common but true statin intolerance is uncommon; check CK only for symptoms.
Ezetimibe 10 mg: Blocks intestinal cholesterol absorption (NPC1L1); adds 15%–25% LDL-C lowering.
Bempedoic acid: An option for statin intolerance; can raise uric acid and trigger gout.
PCSK9-directed therapy: Monoclonal antibodies (evolocumab, alirocumab) every 2–4 weeks or the small interfering RNA inclisiran (twice yearly after loading) lower LDL-C by about 50%–60% for patients who remain above goal.
Triglycerides: Statins remain the foundation. Icosapent ethyl reduces events in statin-treated patients with ASCVD or diabetes and triglycerides 150–499 mg/dL; fibrates and omega-3s are used mainly to prevent pancreatitis when triglycerides reach about 1,000 mg/dL.
Statins in Pregnancy & Lactation
In 2021 the FDA asked manufacturers to remove the absolute pregnancy contraindication (the former Category X) so that very-high-risk patients—such as those with homozygous familial hypercholesterolemia or established ASCVD—can make individualized decisions. For most women, practice is unchanged:
Preconception: Use reliable contraception while on a statin, and stop it about 1–2 months before trying to conceive, or as soon as pregnancy is recognized.
Pregnancy: LDL-C rises about 30%–50% and triglycerides often double or triple by the third trimester, so routine lipid checks are deferred. Bile acid sequestrants (such as colesevelam) are the usual option if lipid lowering is essential; severe familial hypercholesterolemia may need lipoprotein apheresis.
Breastfeeding: Statins are not recommended during lactation; resume after weaning.